BIOCON₹343.00-3.30%
Group Companies
Foreign Flows
sector level — not this stockHealthcare sector+₹3 Crnet foreign buying
2026-09-16 to 2026-09-endThis is the flow into the whole Healthcare sector, not into BIOCON. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.
Supply Chain
suppliers and customers in the graphMacro Sensitivity
rates, currency, commoditiesRevenue by Segment
Business Group
Geographic Exposure
revenue, imports, currencyScenario analysis
stated assumptions, shown workingsBIOCON exposure summary
In its latest segment disclosure (Mar 2026), Biosimilars was the largest segment at 59.4% of segment revenue, followed by CRDMO at 22.3%. Biocon Limited is a constituent of 9 indices, with its largest weights in NIFTY Pharma (2.60%), NIFTY Healthcare Index (2.21%), NIFTY Midcap 100 (0.75%). 12 exchange-traded funds hold the stock.
| Index memberships | 9 |
|---|---|
| ETFs holding | 12 |
| Largest segment | Biosimilars · 59.4% |